ASTIN: a Bayesian Adaptive Dose-response Trial in Acute Stroke
Overview
Authors
Affiliations
Understanding the dose-response is critical for successful drug development. We describe an adaptive design to efficiently learn about the dose-response and the ED95. A dynamic termination rule allows for early discontinuation either for efficacy or futility. The design was deployed in ASTIN, a phase II proof-of-concept trial of the neuroprotectant, neutrophil inhibitory factor (NIF), in acute stroke. We discuss the learning from this trial.
The case for neuregulin-1 as a clinical treatment for stroke.
Noll J, Sherafat A, Ford G, Ford B Front Cell Neurosci. 2024; 18:1325630.
PMID: 38638304 PMC: 11024452. DOI: 10.3389/fncel.2024.1325630.
Targeted randomization dose optimization trials enable fractional dosing of scarce drugs.
Boonstra P, Tabarrok A, Strohbehn G PLoS One. 2023; 18(10):e0287511.
PMID: 37903093 PMC: 10615276. DOI: 10.1371/journal.pone.0287511.
Practical recommendations for implementing a Bayesian adaptive phase I design during a pandemic.
Ewings S, Saunders G, Jaki T, Mozgunov P BMC Med Res Methodol. 2022; 22(1):25.
PMID: 35057758 PMC: 8771176. DOI: 10.1186/s12874-022-01512-0.
Comparison of hierarchical EMAX and NDLM models in dose-response for early phase clinical trials.
Huang X, Gajewski B BMC Med Res Methodol. 2020; 20(1):194.
PMID: 32690004 PMC: 7370408. DOI: 10.1186/s12874-020-01071-2.
Adaptive Signature Design- review of the biomarker guided adaptive phase -III controlled design.
Bhattacharyya A, Rai S Contemp Clin Trials Commun. 2019; 15:100378.
PMID: 31289760 PMC: 6591770. DOI: 10.1016/j.conctc.2019.100378.